English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 914837      Online Users : 1414
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version
    Siblings
    專利 [0/42]
    期刊論文 [141/141]

    Collection Statistics

    近3年內發表的文件:1(2.08%)
    含全文筆數:30(62.50%)

    文件下載次數統計
    下載大於0次:30(100.00%)
    下載大於100次:30(100.00%)
    檔案下載總次數:17910(17.57%)

    最後更新時間: 2024-12-01 08:33


    Top Upload

    Loading...

    Top Download

    Loading...

    RSS Feed RSS Feed
    Jump to a point in the index:
    Or type in a year:
    Ordering With Most Recent First Show Oldest First

    Showing items 1-48 of 48. (1 Page(s) Totally)
    1 
    View [10|25|50] records per page

    DateTitleRelation
    2023-10 Discovery of novel AXL and MER inhibitors as potential anticancer and immune modulator drugs Annals of Oncology. 2023 Oct;34(Suppl. 2):S214.
    2019-10 The molecular mechanisms of EpCAM in regulating tumor progression and development of anti-EpCAM antibodies for colon cancer diagnosis and therapy Annals of Oncology. 2019 Oct;30(Suppl. 5):786.
    2019-10 Discovery of clinical candidate DBPR112, a furanopyrimidine-based epidermal growth factor receptor inhibitor for the treatment of non-small cell lung cancer Annals of Oncology. 2019 Oct;30(Suppl. 5):789.
    2018-07 Clinical candidate DBPR112: A novel epidermal growth factor receptor inhibitor as a promising treatment for non-small cell lung cancer Cancer Research. 2018 Jul;78(13, Suppl.):Meeting Abstract 4789.
    2018-07 Blockage of EGFR signaling repurposes tumor metabolism through suppression of glycolysis and Kreb cycle in head and neck cancer Cancer Research. 2018 Jul;78(13, Suppl.):Meeting Abstract 3944.
    2018-01 Discovery and development of DBPR112 as a clinical candidate: A novel EGFR inhibitor for non-small cell lung cancer Cancer Science. 2018 Jan;109(Suppl. 1):739.
    2017-04 Toward the total syntheses of natural products containing trans-decalin skeleton from masked o-benzoquinone Abstracts of Papers of the American Chemical Society. 2017 Apr;253:Meeting Abstract 516.
    2017-04 Discovery of BPR1K871-a quinazoline based multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation Abstracts of Papers of the American Chemical Society. 2017 Apr;253:Meeting Abstract 482.
    2017-04 One-pot tandem oxidative dearomatization/ 4+3 cycloaddition: Masked o-benzoquinone with diaza-oxyallyl cation Abstracts of Papers of the American Chemical Society. 2017 Apr;253:Meeting Abstract 185.
    2015-08 BPR2P001S0, a Coumarin derivative, induced cell cycle arrest in A549 through inhibiting PDPK1 activity Cancer Research. 2015 Aug;75:Abstract number 1754.
    2015-08 Optimization of furanopyrimidine-based kinase inhibitors: Identification of a BTK kinase inhibitor for the treatment of B cell lymphoma Abstracts of Papers of the American Chemical Society. 2015 Aug;250:Meeting Abstract 180.
    2015-08 Discovery of 2,4-diaminopyrimidines bearing a unique pharmacophore as anaplastic lymphoma kinase inhibitors Abstracts of Papers of the American Chemical Society. 2015 Aug;250:Meeting Abstract 182.
    2015-08 Optimization of quinazoline-based kinase inhibitors: Identification of a dual FLT3/AURKA kinase inhibitor for the treatment of acute myeloid leukemia Abstracts of Papers of the American Chemical Society. 2015 Aug;250:Meeting Abstract 490.
    2014-11 Discovery of multiple kinases inhibitors, DBPR114, as the novel anti-cancer agent European Journal of Cancer. 2014 Nov;50(Suppl. 6):92-93.
    2014-11 CDKN1A-mediated responsiveness of MLL-AF4-positive acute lymphoblastic leukemia to Aurora kinase-A inhibitors European Journal of Cancer. 2014 Nov;50(Suppl. 6):19-20.
    2014-10 Optimization of 5,6-fused pyrimidine-based kinase inhibitors by computer-aided drug design for the treatment of AML Cancer Research. 2014 Oct;74(19 Suppl.):Abstract No. 2530.
    2014-10 Novel irreversible EGFR tyrosine kinase inhibitor, DBPR112, as a therapeutic candidate for lung adenocarcinoma Cancer Research. 2014 Oct;74(19 Suppl.):Abstract No. 1756.
    2014-03 Efficient virtual screening using ligand efficiency based approach Abstracts of Papers - American Chemical Society. 2014 Mar;247:Article number 55-MEDI.
    2014-03 DBPR112, a potent and selective EGFR kinase inhibitor in preclinical study Abstracts of Papers - American Chemical Society. 2014 Mar;247:Article number 315-MEDI.
    2013-11 Peptide-mediated liposomal doxorubicin enhances drug delivery efficiency and therapeutic efficacy in lung cancer animal models Journal of Thoracic Oncology. 2013 Nov;8(Suppl. 2):S779.
    2013-11 A development drug candidate targeting EGFR kinase for lung cancer: DBPR112 Journal of Thoracic Oncology. 2013 Nov;8(Suppl. 2):S779-S780.
    2013-04-07 BPR000K, a novel Aurora kinase inhibitor Abstracts of Papers - American Chemical Society. 2013 Apr 7;245:Article number 300-MEDI.
    2013-04-07 Kinase-focused library: Design and synthesis of pyrimidines derivatives bearing amino substituents using high throughput parallel synthesis Abstracts of Papers - American Chemical Society. 2013 Apr 7;245:Article number 298-MEDI
    2013-04-07 3D-QSAR assisted drug design: Identification of a potent quinazoline based Aurora kinase inhibitor Abstracts of Papers - American Chemical Society. 2013 Apr 7;245:Article number 87-MEDI.
    2013-04-07 Development drug candidate targeting EGFR kinase: DBPR112 Abstracts of Papers - American Chemical Society. 2013 Apr 7;245:Article number 299-MEDI.
    2013-04 Design and synthesis of Aurora kinase inhibitors as anticancer agents Abstracts of Papers - American Chemical Society. 2013 Apr;245:Article number 301-MEDI.
    2012-03-25 Design, synthesis, and SAR studies of duel FLT-3 and Aurora kinase inhibitors Abstracts of Papers - American Chemical Society. 2012 Mar 25;243:Article number 48-MEDI.
    2011-09-23 BPR1K653, a novel Aurora Kinase Inhibitor, exhibits potent anti-proliferative activity in P-gp170 (MDR1)-mediated VX680-resistant cancer cells in vitro and in vivo European Journal of Cancer. 2011 Sep 23;47:S127.
    2011-04 Antivascular activities of novel tubulin binding agent BPR0L075 Cancer Research. 2011 Apr;71:Abstract number 5309.
    2011-03-27 Design and synthesis of potent Aurora kinase inhibitors Abstracts of Papers - American Chemical Society. 2011 Mar 27;241:258-MEDI.
    2011-03 SAR studies of quinoline derivatives as novel anti-influenza agents Abstracts of Papers - American Chemical Society. 2011 Mar;241:81-MEDI.
    2011-03 Potent EGFR tyrosine kinase inhibitors as anticancer agents Abstracts of Papers - American Chemical Society. 2011 Mar;241:257-MEDI.
    2010-08 Lead optimization of furanopyrimidine Aurora kinase inhibitors: Development of in vivo active agents in tumor xenograft models Abstracts of Papers - American Chemical Society. 2010 Aug;240:MEDI 332.
    2009-09 Fast-forwarding kinase drug discovery: aurora and EGFR kinase inhibitor lead development EJC Supplements. 2009 Sep;7(2):96.
    2009-05 Down-regulation of survivin enhances sensitivity to BPROL075 in human cancer cells via caspase-independent mechanisms Cancer Research. 2009 May;69:Abstract number 5542.
    2009-03 Discovery and development of novel furano-pyrimidine analogs as Aurora kinase inhibitors Abstracts of Papers - American Chemical Society. 2009 Mar;237:MEDI 221.
    2007-07 Anti-influenza drug discovery Drugs of the Future. 2007 Jul;32(Suppl. A):97.
    2007-07 From bench to drug candidate: Design and synthesis of 5,6-fused heteroaromatics as anticancer agents Drugs of the Future. 2007 Jul;32(Suppl. A):34-35.
    2006-11 Combined modalities of resistance in an oxaliplaitin-resistant human gastric cancer cell line with enhanced sensitivity EJC Supplements. 2006 Nov;4(12):59.
    2006-09 MEDI 416-3- 2-((2S)-2-Cyano-pyrrolidin-1-yl)-2-oxo-ethylamino -3-methyl-butyr amide analogs as DPP-IV inhibitors for the treatment of type-II diabetes Abstracts of Papers - American Chemical Society. 2006 Sep;232:MEDI 416.
    2005-03 Promazine analogues as potential anti SARS-CoV drugs Abstracts of Papers of the American Chemical Society. 2005 Mar;229(Part 2):U168.
    2005-03 Design, synthesis and sar of indole-based PPAR agonists Abstracts of Papers of the American Chemical Society. 2005 Mar;229(Part 2):U141.
    2005-03 Design and structure-activity relationships of novel indole-based PPAR agonists as antidiabetic agents Abstracts of Papers of the American Chemical Society. 2005 Mar;229(Part 2):U141.
    2004-09 Drug design of BPR0L075 as an anticancer agent World Conference on Magic Bullets - Celebrating Paul Ehrlich's 150th Birthday. 2004 Sep 9-11:Abstract # 203.
    2004-08-22 Concise synthesis and structure-activity relationships of combretastatin A-4 analogues, 1-aroylindoles and 3-aroylindoles, as novel classes of potent antitubulin agents Abstracts of Papers - American Chemical Society. 2004 Aug 22;228:U924.
    2004-07 Drug design for BPR0L075 as an anticancer agent Medicine in the 21st Century Tri-Conference & Bio-Forum 2004 Shanghai International Convention Center. 2004 Jul.
    2003 The synthetic 1-aroylindoles and 3-aroylindoles derivatives, combretastatin A-4 analogues, as a novel class of potent anticancer agents 2003 PSROC Annual Meeting. 2003.
    2002-08 Synthesis and structure-activity relationship of 2-aminobenzophenone derivatives as antimitotic agents Abstracts of Papers of the American Chemical Society. 2002 Aug;224:076-MEDI.

    Showing items 1-48 of 48. (1 Page(s) Totally)
    1 
    View [10|25|50] records per page

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback